Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117858 | 1.00 | OPRK1 (0.43) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2117864 | 1.00 | OPRK1 (0.43) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2610407 | 0.92 | OPRK1 (0.37) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2118616 | 0.89 | HTR2A (0.37) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2118621 | 0.89 | HTR2A (0.37) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2120638 | 0.89 | OPRK1 (0.35) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2610410 | 0.88 | CYP3A4 (0.37) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL9950738 | 0.87 | CYP3A4 (0.39) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL9951170 | 0.87 | CYP3A4 (0.39) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL2119184 | 0.83 | HTT (0.35) | OPRK1CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | OPRK1 61/4885CYP3A4 2390/4885HTT 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.